Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718 – Benzinga

Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718BenzingaVerastem (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it has acquired the license to VS-4718 held originally by Poniard Pharmaceuticals. The previous and and more read more
http://blog.zandcell.com/verastem-acquires-rights-to-cancer-stem-cell-inhibitor-vs-4718-benzinga/?utm_source=rss&utm_medium=rss&utm_campaign=verastem-acquires-rights-to-cancer-stem-cell-inhibitor-vs-4718-benzinga